Amedisys Inc. (NASDAQ:AMED) has been given a $60.00 target price by equities researchers at Craig Hallum in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the stock. Craig Hallum’s price objective would indicate a potential upside of 30.98% from the company’s current price.
A number of other equities analysts have also recently weighed in on AMED. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Friday, November 4th. They noted that the move was a valuation call. Jefferies Group reaffirmed a “buy” rating and set a $50.00 price target (down from $59.00) on shares of Amedisys in a research note on Tuesday, November 1st. Finally, Zacks Investment Research raised shares of Amedisys from a “sell” rating to a “hold” rating in a research note on Monday, January 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Amedisys currently has a consensus rating of “Hold” and an average target price of $53.29.
Amedisys (NASDAQ:AMED) opened at 45.81 on Tuesday. Amedisys has a 52 week low of $31.16 and a 52 week high of $55.16. The stock has a market capitalization of $1.54 billion, a P/E ratio of 37.37 and a beta of 1.35. The firm’s 50-day moving average is $42.34 and its 200-day moving average is $46.01.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $0.36 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.44 by $0.08. Amedisys had a return on equity of 11.94% and a net margin of 2.93%. The company had revenue of $361.60 million for the quarter, compared to analyst estimates of $361.08 million. During the same period last year, the company earned $0.34 earnings per share. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. On average, equities research analysts predict that Amedisys will post $1.49 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. Profund Advisors LLC boosted its stake in Amedisys by 1.1% in the second quarter. Profund Advisors LLC now owns 5,910 shares of the company’s stock valued at $298,000 after buying an additional 66 shares in the last quarter. Arizona State Retirement System boosted its stake in Amedisys by 0.7% in the second quarter. Arizona State Retirement System now owns 14,550 shares of the company’s stock valued at $734,000 after buying an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in Amedisys by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 6,230 shares of the company’s stock valued at $296,000 after buying an additional 100 shares in the last quarter. PineBridge Investments L.P. boosted its stake in Amedisys by 2.9% in the second quarter. PineBridge Investments L.P. now owns 3,560 shares of the company’s stock valued at $180,000 after buying an additional 101 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Amedisys by 1.0% in the third quarter. Bank of Montreal Can now owns 15,617 shares of the company’s stock valued at $741,000 after buying an additional 158 shares during the last quarter. 93.52% of the stock is currently owned by institutional investors.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.